95299-16-4

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-(3,5-bis(trifluoromethyl)phenyl)acetate is utilized as a building block for the synthesis of various drugs. Its unique molecular structure and fluorinated phenyl group contribute to the development of new chemical entities with desirable properties, enhancing the therapeutic potential of resulting pharmaceuticals.
Used in Agrochemical Industry:
In the agrochemical sector, methyl 2-(3,5-bis(trifluoromethyl)phenyl)acetate serves as a key intermediate for the production of pesticides and herbicides. Its stability and low reactivity make it a valuable component in the creation of effective and long-lasting agrochemical products designed to protect crops and control pests.

Upstream product

• 67-56-1 methanol 
• 85068-33-3 3,5-bistrifluoromethylphenyl acetic acid 
• 328-70-1 3,6-bis(trifluoromethyl)bromobenzene 
• 108-59-8 malonic acid dimethyl ester 
• 1360789-01-0 2-(3,5-bis(trifluoromethyl)phenyl)-1-(2,2,6,6-tetramethylpiperidin-1-yl)ethanone 
• 64-17-5 ethanol 

Downstream Products

• 170291-48-2 methyl α-diazo-3,5-bis(trifluoromethyl)benzeneacetate 
• 170291-46-0 methyl 2-[(N-tert-butoxycarbonyl-4-phenylpiperidin-4-yl)methoxy]-2-(3,5-bis(trifluoromethyl)phenyl)acetate 
• 170291-49-3 2-(1-tert-Butoxycarbonyl-4-phenylpiperidine-4-yl)methoxy-2-(3,5-bis(trifluoromethyl)phenyl)acetic acid 
• 1025823-00-0 4-[(3,5-bis-trifluoromethyl-phenyl)-chlorocarbonyl-methoxymethyl]-4-phenyl-piperidine-1-carboxylic acid tert-butyl ester 
• 170291-50-6 N-{2-[(N-tert-butoxycarbonyl-4-phenylpiperidin-4-yl)methoxy]-2-(3,5-bis(trifluoromethyl)phenyl)acetyl}-4(R)-benzyl-2-oxazolidinone 
• 1491169-19-7 2-(3,5-bis(trifluoromethyl)phenyl)-2-((4-(2-fluorophenyl)pyridin-3-yl)methylamino)acetic acid methyl ester 
• 374794-36-2 2-(3,5-bistrifluoromethylphenyl)methyl propionate 
• 710324-52-0 2-(3,5-Bis-trifluoromethyl-phenyl)-3-(2,4-dichloro-pyrimidin-5-yl)-propionic acid methyl ester 
• 334477-28-0 methyl 2-(3,5-bis(trifluoromethyl)phenyl)acrylate 
• 85068-33-3 3,5-bistrifluoromethylphenyl acetic acid 

Relevant academic research and scientific papers

Five-membered azole heterocyclic compound and its preparation method, pharmaceutical composition and use thereof

The present invention relates to a five-membered azole heterocycle compound represented by the following general formula (I), a preparation method of the five-membered azole heterocycle compound, a drug composition of the five-membered azole heterocycle compound, and a use of the five-membered azole heterocycle compound in preparation of drugs for prevention or treatment of TGR5-mediated diseases. The formula (I) is represented by the instruction.

Design, synthesis, and structure-activity relationships of 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazoles as TGR5 agonists

Given its role in the mediation of energy and glucose homeostasis, the G-protein-coupled bile acid receptor1 (TGR5) is considered a potential target for the treatment of type2 diabetes mellitus and other metabolic disorders. By thorough analysis of diverse structures of published TGR5 agonists, a hypothetical ligand-based pharmacophore model was built, and a new class of potent TGR5 agonists, based on the novel 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazole core, was discovered by rational design. Three distinct synthetic methods for constructing 4,5-dihydro-1,2,4-oxadiazoles and extensive structure-activity relationship studies are reported herein. Compound (R)-54n, the structure of which was determined by single-crystal X-ray diffraction and quantum chemical solid-state TDDFT-ECD calculations, showed the best potency, with an EC50 value of 1.4nM toward hTGR5. Its favorable properties invitro warrant further investigation.

Switching pathways: Room-temperature neutral solvolysis and substitution of amides

Stick or twist: By introducing steric hindrance at the nitrogen atom, stable linear amides bearing an electron-withdrawing α-substituent (Z=Ar, PhSO2, P(O)(OR)2, CN, or CO2R) can be induced to undergo solvolysis and substitution reactions through an elimination-addition mechanism (see picture). Key to this process is a low barrier to rotation around the amide bond and the α-substituentZ. Copyright

Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases

Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylamino compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several disorders, including multiple sclerosis and stroke.

PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME

The present invention is to provide a piperidine compound represented by the formula [I]: wherein Ring A is an optionally substituted benzene ring, Ring B is an optionally substituted benzene ring, R1 is hydrogen atom or a substituent for amino group, R2 is hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom, Z is oxygen atom or -N(R3)-, R3 is hydrogen atom or an optionally substituted alkyl group, R4a and R4b may be the same or different, and each is hydrogen atom or an optionally substituted alkyl group, or a pharmaceutically acceptable salt thereof, which has an excellent tachykinin receptor antagonistic action.

1-AMIDO-4-PHENYL-4-BENZYLOXYMETHYL-PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROKININ-1(NK-1) ANTAGONISTS FOR THE TREATMENT OF EMESIS, DEPRESSION, ANXIETY AND COUGH

Disclosed are NK1 antagonists having the formula: Also disclosed are uses of compounds of formula (I) for the manufacture of a medicament for treating a number of physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

Novel dihydropyridinone compounds

Disclosed are novel dihydropridinone compounds that are selective inhibitors of both KDR and FGFR kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast, colon lung and prostate tumors. Also, disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer.

Cyclohexyl derivatives and their use as therapeutic agents

The present invention relates compounds of the formula (I): wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of: (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l) and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R?17, R18, R19, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.

Cyclohexane derivatives and their use as therapeutic agents

The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R17, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.

Process for preparing [bis-(trifluoromethyl)-phenyl]-acetic acids and alkyl esters thereof and dialkyl [bis-(trifluoromethyl)-phenyl]-malonates

[Bis-(trifluoromethyl)-phenyl]-acetic acids are obtained in an advantageous manner by reacting an appropriate bromo- or iodo-bis-(trifluoromethyl)-benzene with a di-C1-C4-alkyl malonate in the presence of a deprotonating agent and a copper salt and hydrolysing and decarboxylating the reaction product in basic medium. It is possible to obtain a mixture of alkyl [bis-(trifluoromethyl)-phenyl]-acetate and alkyl [bis-(tri-fluoromethyl)-phenyl]-malonate by admixing the reaction mixture which is present before hydrolysis and complete decarboxylation with water and acid and heating. From the mixture, it is possible to obtain alkyl [bis-(trifluoromethyl)-phenyl]-acetate by distillation under reduced pressure and dialkyl [bis-(trifluoromethyl)-phenyl]-malonate by work-up by column chromatography, fractional distillation or film distillation. [Bis-(trifluoromethyl)-phenyl]-malonic esters are novel compounds.